BOLT Stock — Bolt Biotherapeutics Inc.: Cash, EV, Pipeline

What they do

Our mission is to harness the power of the immune system to improve lives and eradicate cancer. This often means that our product candidates take new and unproven approaches to treating cancer. We believe that taking smart risks is critical to making breakthroughs.

Source: 10-K FY2025 via SEC EDGAR

Share price

$6.54

Market cap

$12.6M

Cash

$133.1M

Enterprise value

-$120.5M

Balance sheet

Cash	$133.1M
Debt	$0.0M
Net cash	$133.1M
Enterprise value	-$120.5M
Basic shares	2.4M shares
Fully diluted shares	40.5M shares
Fully diluted market cap	$264.8M
Cash per share	$56.47
Quarterly burn	$6.5M
Cash runway	20.4 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

2.4M

Pre-funded warrants

0.0M

Options

0.5M

RSUs

0.2M

Warrants

7.0M

Converts

0.0M

Conv preferred

30.4M

ESPP reserve

0.1M

FDSO

40.5M

Cap table as of 2026-10-23.

Price history

Loading BOLT daily closes…

Loading price history…

Next catalyst

BDC-4182 · Now - Nov 30, 2026 · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDNow - Nov 30, 2026 Now	BDC-4182 Initial Phase 1/2 data in gastric/gastroesophageal cancer · NCT06921837	Phase 1/2	gastric/gastroesophageal cancer	Nov 2026
Jun 12 - Jul 24 in 7 mo	BDC-4182	Phase 2	Gastric Cancer Adenocarcinoma Metastatic; Gastroesophageal Adenocarcinoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

BDC-4182

Phase 1 · Active Modality: immune-stimulating antibody conjugate (ISAC)

Target claudin 18.2

Partnerships Innovent Biologics: exclusive worldwide rights secured March 2024 (restructured collaboration); Innovent eligible for commercial/sales milestones and royalties on global net sales

Indications

gastric/gastroesophageal junction cancer (Phase 1)

Status note First-in-human Phase 1 dose escalation and expansion trial ongoing (RP2D selection goal); only pipeline program in active development per this filing. Genmab oncology R&D collaboration (research-stage, evaluating ISAC concepts) is platform-level. BDC-3042 and trastuzumab imbotolimod (former lead) referenced but described as on hold or superseded, not in active development.

CEA ISAC

Stage not disclosed · Active Modality: immune-stimulating antibody conjugate (ISAC)

Target CEA (carcinoembryonic antigen cell adhesion molecule 5)

Indications

solid tumors (Stage not disclosed)

Status note Boltbody ISAC targeting CEA, expressed in various solid tumors including colorectal, NSCLC, pancreatic and breast. Program can be quickly restarted per this filing; preclinical activity described. Filing also names a PD-L1 ISAC as similarly restartable.

Toray collaboration ISAC

Stage not disclosed · Active Modality: immune-stimulating antibody conjugate (ISAC)

Partnerships Toray Industries: joint development and license agreement (2019) for a Boltbody ISAC using Toray's proprietary antibody; obligation through completion of first Phase 1 trial

Indications

cancer (Stage not disclosed)

Status note Collaboration product candidate; target and indication not disclosed in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	BDC-4182
Lead indication	Gastric Cancer Adenocarcinoma Metastatic
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06921837	Phase 2	Recruiting	Sponsor	BOLT	—	Gastric Cancer Adenocarcinoma Metastatic; Gastroesophageal Adenocarcinoma	Nov 2026

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Bolt Biotherapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Vivo Capital	72,414	no change	0.03%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

BOLT — Bolt Biotherapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

BOLT — Bolt Biotherapeutics Inc.